Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
더 읽어보세요 2020-06-16뉴스 목록
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
The first c-Met inhibitor approved by the FDA to market
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
더 읽어보세요 2020-05-18
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe
더 읽어보세요 2020-04-09
Fapilavir completes clinical research and shows good clinical efficacy
On March 17th, the State Council's joint prevention and control mechanism held a press conferenc
더 읽어보세요 2020-03-22
Migraine relieved within 1 hour, FDA approves new oral medication
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito
더 읽어보세요 2020-03-01
Insomnia and schizophrenia innovative treatments approved
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide
더 읽어보세요 2020-02-03
First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti
더 읽어보세요 2020-01-09
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22
더 읽어보세요 2019-12-21
Roche T + A immunotherapy research achieves historic breakthrough
November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical
더 읽어보세요 2019-12-12
Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing
Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr
더 읽어보세요 2019-11-19